Methylcobalamin has an excellent safety profile with no established upper limit for toxicity
Selective Inhibitor Small Molecule Salvage Pathway Published Studies Selective and potent inhibition of nicotinamide N-methyltransferase 5-Amino-1MQ has been shown to inhibit NNMT with high selectivity, leading to increased intracellular NAD+ levels and SAM (S-adenosylmethionine) concentrations in adipose tissue
However, it is important to understand that 24 weeks, while substantial for clinical trials, provides limited information about safety with years-long continuous use
This documentation must come from the prescribing provider and typically needs to specify the clinical reason for compounding, such as: Allergy to an inactive ingredient in the commercial product Need for a dose not available in commercial presentations Documented intolerance to the commercial delivery device Billing compounded tirzepatide through the pharmacy benefit uses standard pharmacy claim formats (NCPDP) with the compounding pharmacy NDC
isolated mildly elevated B12 in well individuals taking supplements typically requires only cessation and repeat testing after 812 weeks
This yields a total weekly dose of 1,500 IU
